Zacks Research Issues Optimistic Forecast for ORMP Earnings

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) – Stock analysts at Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for shares of Oramed Pharmaceuticals in a note issued to investors on Thursday, June 18th. Zacks Research analyst M. Marin now anticipates that the biotechnology company will post earnings of $0.43 per share for the quarter, up from their prior forecast of $0.15. The consensus estimate for Oramed Pharmaceuticals’ current full-year earnings is $0.71 per share. Zacks Research also issued estimates for Oramed Pharmaceuticals’ Q3 2026 earnings at $0.52 EPS and Q4 2026 earnings at $0.46 EPS.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its quarterly earnings data on Friday, March 27th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02.

Separately, Weiss Ratings upgraded shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Oramed Pharmaceuticals Trading Up 4.0%

NASDAQ ORMP opened at $4.17 on Wednesday. Oramed Pharmaceuticals has a 12 month low of $1.98 and a 12 month high of $5.01. The stock has a market cap of $170.68 million, a price-to-earnings ratio of 1.61 and a beta of 1.26. The company’s 50 day moving average is $3.98 and its two-hundred day moving average is $3.54.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Several large investors have recently made changes to their positions in ORMP. Jane Street Group LLC grew its position in shares of Oramed Pharmaceuticals by 35.3% during the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 17,510 shares in the last quarter. Bank of America Corp DE raised its stake in Oramed Pharmaceuticals by 4.4% during the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 6,261 shares during the period. HRT Financial LP purchased a new position in Oramed Pharmaceuticals in the 4th quarter worth approximately $131,000. Marshall Wace LLP purchased a new position in Oramed Pharmaceuticals in the 4th quarter worth approximately $738,000. Finally, Squarepoint Ops LLC boosted its stake in Oramed Pharmaceuticals by 95.1% in the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 28,406 shares during the period. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.